. Author manuscript; available in PMC: 2022 Mar 30.

Published in final edited form as: J Am Coll Cardiol. 2021 Mar 30;77(12):1503–1516. doi: 10.1016/j.jacc.2021.01.050

Table 5:

Major adverse cardiovascular events (MACE) in all patients and in those dichotomized based on normal versus abnormal T1 values.

	All patients (n=86)	Abnormal T1 values^* (n=67)	Normal T1 values (n=19)	P value
Follow-up time for MACE^†, days	158 (78, 333)	161 (78, 333)	154 (68, 407)	0.92
MACE^‡	27 (31.4)	27 (40.3)	0 (0)	<0.001
• Complete heart block	8 (9.5)	8 (12.1)	0 (0)	0.19
• Cardiogenic shock	10 (12.1)	10 (15.4)	0 (0)	0.11
• Cardiac arrest	12 (14.5)	12 (18.5)	0 (0)	0.072
• Cardiovascular death	12 (14.0)	12 (17.9)	0 (0)	0.061

Abnormal T1 values were defined as values >2 standard deviation above the site, CMR vendor/field strength specific reference ranges

^†

Time of the MACE was defined by the date of the earliest event when multiple MACE happened.

^‡

Patients may have multiple MACE.